Dr. Lal PathLabs Launches India’s First Comprehensive Complement Lab
Filing Summary
Dr. Lal PathLabs has introduced India’s first Comprehensive Complement Testing Laboratory. This facility offers several tests for the first time in the country, enhancing autoimmune diagnosis capabilities. The lab utilizes advanced immunoturbidimetric and ELISA platforms, adhering to CAP and NABL standards. The launch addresses the increasing recognition of autoimmune and inflammatory diseases in India. As of March 31, 2025, Dr. Lal PathLabs operates 298 clinical laboratories and 6,607 Patient Service Centers. The company aims to improve diagnostic accuracy and treatment outcomes for autoimmune and kidney diseases.
Dr. Lal PathLabs has announced the launch of India’s first Comprehensive Complement Testing Laboratory. This facility introduces several complement assays to the Indian market for the first time. The laboratory aims to enhance the diagnosis of autoimmune, kidney, and recurrent infection-related conditions. The facility is equipped with advanced immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards.
The press release does not specify any financial terms or payment structures related to the launch of the Comprehensive Complement Testing Laboratory. The focus remains on the operational and diagnostic capabilities of the new facility.
The scope of the new laboratory includes offering complement assays such as C1q, C5, Factor B, Factor H antibody, AH50, and C1 INH functional. These tests are designed to measure immune proteins like C3, C4, and C5, which help identify whether the immune response is overactive, underactive, or malfunctioning. This is crucial for diagnosing and managing autoimmune diseases early. The laboratory aims to bridge the gap between research and routine clinical care by providing functional and antibody-based complement assays.
The launch of the Comprehensive Complement Testing Laboratory comes in response to the increasing recognition of autoimmune and inflammatory diseases in India. Reports indicate a 30% increase in autoimmune disorders post-pandemic, with a significant rise among individuals aged 31–45 years. Additionally, nearly 70% of autoimmune patients in India are women, as highlighted at IRACON 2025. The new facility aims to provide earlier and more accurate diagnosis and treatment for these conditions.
The press release does not specify any timeline or milestones for the implementation of the new laboratory. The announcement focuses on the operational capabilities and diagnostic advancements offered by the facility.
Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. The company operates an integrated, nationwide network offering a broad range of diagnostic and related healthcare tests and services. As of March 31, 2025, Dr. Lal PathLabs has 298 clinical laboratories, including a National Reference Lab in Delhi and Regional Reference Labs in Kolkata, Bangalore, and Mumbai, along with 6,607 Patient Service Centers and 12,365 Pick-up Points. The company’s customers include individual patients, hospitals, healthcare providers, and corporate clients.